Alex Rosen
Directeur/Membre du Conseil chez Upstream Bio, Inc.
Profil
Alex Rosen is currently working as a Director at Upstream Bio, Inc. Prior to this, he worked as a Biotech Investor at Venrock Associates.
Mr. Rosen holds a doctorate degree from the University of Pennsylvania, an undergraduate degree from Princeton University, and an MBA from The Wharton School of the University of Pennsylvania.
Postes actifs de Alex Rosen
| Sociétés | Poste | Début |
|---|---|---|
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Directeur/Membre du Conseil | 08/06/2023 |
Anciens postes connus de Alex Rosen
| Sociétés | Poste | Fin |
|---|---|---|
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Private Equity Investor | - |
Formation de Alex Rosen
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
